Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC_ [360p]
